Avoiding Steady-State and Wash-In Simulation Errors

Why Dosing History and Simulation Duration Matter

An exposure-based probability of target attainment (PTA) is only meaningful when the simulated exposure represents the clinical question. If the question concerns exposure after treatment has reached steady state, calculating exposure too soon can make attainment appear lower than it is at steady state. Conversely, if the question concerns a finite treatment course that begins with no drug in the body, assuming steady state from the first dose can overstate early exposure. A simulation can also answer the wrong question if its dosing duration or exposure window does not match the intended regimen.

The key is to specify both the dosing history before the exposure window and the time interval over which exposure is calculated. “Steady-state PTA” and “PTA during the first treatment interval” are different estimands, even when the dose and target are identical.

Definition: Under a repeated dosing regimen, steady state is reached when the concentration-time profile repeats from one dosing interval to the next. Concentration is not constant during an interval; rather, corresponding concentrations at the same times in successive intervals are equal. A wash-in is a period of dosing before the analysis window, included so that drug can accumulate toward the desired state before exposure is evaluated.

The appropriate simulation depends on the intended setting. A patient starting treatment usually has no prior doses of that treatment, so a simulation of the initial course should begin with the specified initial condition, often zero drug concentration. A steady-state dose comparison instead requires prior dosing, or a valid steady-state initialization, before the exposure window begins. Neither approach is universally correct: the error is using one while interpreting results as the other.

Accumulation and Approach to Steady State

Consider a one-compartment model with instantaneous intravenous bolus doses \(D\) every \(\tau\) hours, constant volume \(V\), and first-order elimination with rate constant \(k=CL/V\). Assume linear pharmacokinetics, constant parameters, and zero concentration before the first dose. Define \(r=e^{-k\tau}\), the fraction of a concentration remaining after one dosing interval. Immediately after the \(n\)th dose, the concentrations contributed by the current and previous doses form a geometric series:

C_{n,\mathrm{peak}}=\frac{D}{V}\left(1+r+r^2+\cdots+r^{n-1}\right) =\frac{D}{V}\frac{1-r^n}{1-r}.

As \(n\) increases, \(r^n\) approaches zero, so the steady-state peak is \(C_{\mathrm{ss,peak}}=(D/V)/(1-r)\). Thus the fraction of the steady-state peak attained after \(n\) doses is \(1-r^n\). This is an exact result under the stated assumptions, not a universal “number of half-lives” rule for every exposure metric or model.

\frac{C_{n,\mathrm{peak}}}{C_{\mathrm{ss,peak}}} =1-e^{-nk\tau}.

The elimination half-life is \(t_{1/2}=\ln(2)/k\). For repeated dosing, accumulation depends on the interval relative to this half-life: a long half-life relative to \(\tau\) means more drug remains from prior doses. The concentration may approach its repeating profile gradually even when the regimen has been administered for several days. A concentration ratio at a particular time is not automatically the same as the ratio for AUC, trough, or another exposure summary.

Worked Example: How Much Accumulation Has Occurred?

Suppose a hypothetical drug follows the one-compartment bolus model above, with a half-life of 36 hours and a dosing interval of 24 hours. Find the fraction of the steady-state peak reached immediately after the third and sixth doses.

First, \(k=\ln(2)/36=0.01925\ \mathrm{h}^{-1}\), so the fraction remaining over one interval is \(r=e^{-k\tau}=e^{-(\ln(2)/36)(24)}=2^{-2/3}\approx0.6300\).

After the third dose, the fraction is \(1-r^3=1-(2^{-2/3})^3=1-2^{-2}=0.7500\). Thus the third-dose peak is 75.00% of the steady-state peak. After the sixth dose, the fraction is \(1-r^6=1-(2^{-2/3})^6=1-2^{-4}=0.9375\). Thus the sixth-dose peak is 93.75% of the steady-state peak. These are peak-concentration comparisons; they do not by themselves establish what fraction of steady-state AUC or trough has been reached.

Finite-Interval AUC Is Not Automatically Steady-State AUC

For the same model, the AUC over an interval depends on how many doses have already been given. For an individual with clearance \(CL\), the AUC during the first interval after a single bolus is the integral of the decaying concentration. Since \(k=CL/V\), it is \(D/CL\) multiplied by the fraction eliminated during that interval. After \(n\) doses, the interval AUC includes contributions from all \(n\) doses and is \(D/CL\) multiplied by \(1-e^{-nk\tau}\). At steady state, it approaches \(D/CL\).

AUC_{0\text{–}\tau,\mathrm{first}} =\frac{D}{CL}\left(1-e^{-k\tau}\right), \qquad AUC_{\tau,\mathrm{ss}}=\frac{D}{CL}.

The distinction is important when defining PTA for an AUC threshold. A simulation that computes AUC over the first interval and then labels it steady-state AUC may classify individuals incorrectly. The same issue applies to other exposure metrics: the window, the location of that window relative to dosing, and any pre-window doses must all be specified.

Worked Example: First-Interval Versus Steady-State AUC PTA

Consider a hypothetical 600 mg intravenous bolus every 24 hours in three simulated individuals. Each has \(V=60\) L, while their clearances are 4, 6, and 8 L/h. Define attainment as \(AUC_{\tau}\geq95\ \mathrm{mg\cdot h/L}\). Calculate PTA in this three-person illustration for the first dosing interval and for steady state.

For the first interval, use \(AUC_{0\text{–}24,\mathrm{first}}=(600/CL)(1-e^{-(CL/60)(24)})\). For \(CL=4\) L/h, this is \(150(1-e^{-1.6})=150(0.7981)=119.7\ \mathrm{mg\cdot h/L}\). For \(CL=6\) L/h, it is \(100(1-e^{-2.4})=100(0.9093)=90.93\ \mathrm{mg\cdot h/L}\). For \(CL=8\) L/h, it is \(75(1-e^{-3.2})=75(0.9592)=71.94\ \mathrm{mg\cdot h/L}\). Only the first individual meets the target, so first-interval attainment is \(1/3=33.33\%\).

At steady state, the interval AUCs are \(600/4=150\), \(600/6=100\), and \(600/8=75\ \mathrm{mg\cdot h/L}\). The first two meet the target, so steady-state attainment is \(2/3=66.67\%\). These percentages describe only the three hypothetical individuals. The difference is not a contradiction: the two calculations answer different questions about exposure at different treatment times.

Match the Simulation to the Clinical Question

Before running a PTA simulation, write down the scenario in time order: initial drug amount or concentration, any dosing before the evaluation window, the full regimen, and the exact exposure window used to classify target attainment. If the question concerns a finite course from treatment initiation, simulate that course from its intended initial condition. If it concerns steady-state exposure, simulate enough prior dosing for the profile to converge, or initialize the model at a verified periodic steady state. Do not count a wash-in period as part of the exposure window unless that is specifically the intended estimand.

Worked Example: A Short Course Can Fail a Steady-State Trough Target

Suppose a hypothetical one-compartment drug is given as a 600 mg bolus every 24 hours. Let \(V=60\) L and the half-life be 24 hours, so each dose adds \(D/V=10\ \mathrm{mg/L}\) to concentration and \(r=e^{-k\tau}=0.5\). Consider a trough target of at least \(9.5\ \mathrm{mg/L}\).

At steady state, the trough immediately before a dose is the sum of the residual concentrations from all previous doses: \(C_{\mathrm{ss,trough}}=(D/V)(r+r^2+\cdots)=10r/(1-r)=10\ \mathrm{mg/L}\). It meets the target.

After three doses at times 0, 24, and 48 hours, the trough immediately before a potential fourth dose at 72 hours is \(10(0.5+0.25+0.125)=8.750\ \mathrm{mg/L}\). It does not meet the target. After seven doses, the trough immediately before the eighth dose at 168 hours is \(10\sum_{j=1}^{7}0.5^j=10(1-0.5^7)=9.9219\ \mathrm{mg/L}\), which does meet it. The seven-dose value is still below the exact steady-state trough of \(10\ \mathrm{mg/L}\). If the actual course ends after three doses, 8.750 mg/L is the relevant trough at 72 hours; adding hypothetical doses to force steady state would misrepresent the treatment course.

Diagnostics, Alternatives, and Limitations

Several checks can reveal a timing or initialization error before it affects dose justification:

Inspect the time axis and dose records. Confirm that doses occur at the intended times, that the analysis window is correctly positioned, and that no dose has been omitted or accidentally added.
Check the initial condition. A zero concentration is appropriate for a genuinely untreated start, not for a patient known to be receiving the drug already. A steady-state initial condition is inappropriate for a first-course simulation unless prior treatment is intended.
Compare with an analytic benchmark. For a linear one-compartment bolus model, compare simulated accumulation, trough, or interval AUC with the corresponding geometric-series or AUC expression. Disagreement can indicate a coding, unit, or window-alignment problem.
Examine convergence across duration. For a steady-state analysis, extend the pre-window dosing period and confirm that the exposure distribution and PTA change negligibly. A fixed number of days is not adequate for every elimination half-life.
Check the exposure window itself. Confirm that an interval AUC is integrated over one full dosing interval and that a trough is evaluated immediately before the next scheduled dose, not at an arbitrary time.

Three approaches are useful, but answer different questions. An analytic steady-state calculation is efficient for simple linear models and is a valuable verification benchmark. A direct finite-course simulation preserves treatment initiation and course duration, making it suitable for early exposure or short-course questions. A wash-in simulation includes prior doses and then evaluates a later window; it can approximate steady state for complex models where a closed-form expression is unavailable. For that approach, convergence should be demonstrated rather than assumed.

The geometric-series derivation relies on instantaneous boluses, linear one-compartment disposition, and constant parameters. Oral absorption, multiple compartments, nonlinear elimination, time-varying clearance, or changing covariates can alter the rate and pattern of approach to steady state. In such cases, numerical simulation may be needed, and simple half-life rules may be misleading. Also verify that the simulated duration corresponds to the regimen being justified: treatment duration, wash-in duration, and exposure-window duration are not interchangeable.

Common Mistakes

Wrong reasoning: “The simulation ran for several days, so it must be at steady state.” Correction: Accumulation depends on the model and dosing interval. Check convergence in the relevant exposure metric or compare with a benchmark.
Wrong reasoning: “The first interval’s AUC is the steady-state AUC because the dose is the same.” Correction: Prior doses contribute to steady-state exposure. Under the linear bolus model, the first interval AUC is \(D/CL(1-e^{-k\tau})\), whereas steady-state interval AUC is \(D/CL\).
Wrong reasoning: “Every simulation should include wash-in.” Correction: Wash-in is needed to represent prior dosing or steady state, but it is not appropriate when the intended scenario is treatment initiation with no prior drug.

Key takeaway: PTA depends on the exposure definition and the simulated dosing history. Label the result with its regimen, treatment time, initial condition, and exposure window; verify steady state rather than presuming it.

Check Your Understanding

Answer each question, then compare with the brief solutions.

For a linear bolus model, what does steady state mean: constant concentration or a repeating concentration-time profile?
A simulated patient has no prior treatment. Is it appropriate to assume steady state at the first dose when the question concerns the initial treatment interval?
For a hypothetical one-compartment bolus regimen with \(r=0.8\), what fraction of the steady-state peak is reached immediately after four doses?
Why can extending the simulated treatment duration change PTA even when dose and target are unchanged?

Solutions. (1) It means the concentration-time profile repeats each dosing interval; concentration still rises and falls within the interval. (2) No. Use the intended treatment-start initial condition and evaluate the first interval. (3) The fraction is \(1-r^4=1-0.8^4=1-0.4096=0.5904\), or 59.04%. (4) Longer dosing allows accumulation toward the repeating profile, changing exposure in a later window; this can change which simulated individuals meet the target.